Login to Your Account



'A complete game-changer' as Ablynx's caplacizumab scores in phase III aTTP trial

By Nuala Moran
Staff Writer

Monday, October 2, 2017

LONDON – Shares in Ablynx NV rose by 25.8 percent on Monday to €15.50 (US$18.20) when the company announced positive results from the phase III study of caplacizumab in the treatment of rare blood coagulation disorder acquired thrombotic thrombocytopenic purpura (aTTP).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription